Full-Time

Specialized Nurse Practitioner

Posted on 1/31/2026

Altasciences

Altasciences

1,001-5,000 employees

Integrated CRO for early-phase drug development

No salary listed

Montreal, QC, Canada

In Person

On-site role in Montreal (1200 Beaumont); accessible by public transit.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Google Cloud Platform
Requirements
  • SNP title holder
  • Licence from the Ordre des infirmiers et infirmières du Quebec (OIIQ) required
  • Excellent communication skills in both French and English
  • Advanced Cardiac Life Support (ACLS) certification required
  • Experience with similar responsibilities; ideally related to the industry
  • Fluency in English is an essential requirement for the position of Specialized Nurse Practitioner including, but not limited to, for the following reasons: the requirement to have study protocols, designs and clinical research documents written and documented in English as required by industry regulatory agencies.
Responsibilities
  • Supervise the clinical activities for the clinical trial they are assigned.
  • Ensure subject safety at all times, this may include but is not limited to: review of clinical laboratory results and/or other test results.
  • Review and/or performance of vital signs, ECGs or other safety tests.
  • Record and follow-up on Adverse Events.
  • Perform critical trial related tasks and/or make trial related decisions during the course of the trial.
  • Ensure subject eligibility is met based on protocol inclusionary/exclusionary criteria and that the subject continues to meet eligibility criteria throughout the course of a clinical trial.
  • Ensure requirements related to obtaining informed consent are met.
  • Perform physical examinations and medical history intake and review.
  • Be on-site for surveillance as required by protocol and remain available on-call for medical events.
  • Participate in sponsor visits and regulatory audits.
  • Document study related events incompliance with GCP.
  • Review study protocols and SOPs.
  • Complete and/or review regulatory documents as applicable.
  • May act as Principal Investigator on studies at the discretion of the Chief Medical Officer, Medical Director or Senior Principal Investigator and study sponsor.

Altasciences provides an integrated CRO that handles the full early‑phase drug development path, from preclinical testing through clinical proof of concept and into manufacturing. Its approach combines discovery support, safety testing, clinical trial execution, and in‑house manufacturing to run programs under one roof. This contrasts with competitors that require pharma and biotech clients to source services from multiple vendors, adding complexity and risk; Altasciences streamlines the process by coordinating all steps. The company aims to help innovator drug programs move quickly and efficiently, delivering integrated data to de‑risk decisions and speed progression to later stages.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$6.7M

Headquarters

Laval, Canada

Founded

1976

Simplify Jobs

Simplify's Take

What believers are saying

  • Biotech/pharma consolidation demand for single-vendor early-phase development solutions increases.
  • 3D tissue technology adoption reduces animal testing costs and accelerates regulatory approval timelines.
  • Geographic footprint and participant database enable rapid enrollment for mid-size biopharma sponsors.

What critics are saying

  • Novo Holdings divesting Altasciences signals poor financial performance and operational cutbacks.
  • Charles River aggressive pricing on integrated packages captures 20% mid-size biopharma contracts.
  • AI-driven preclinical platforms from Insilico Medicine displace traditional animal safety pharmacology testing.

What makes Altasciences unique

  • Integrated CRO/CDMO spanning preclinical safety testing through Phase IV bioanalysis and manufacturing.
  • 9 North American facilities with 500,000+ participant database conducting 285+ trials annually.
  • VoxCell partnership integrates 3D tissue technology for human-relevant preclinical testing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Employee Assistance & Telehealth Programs

Remote Work Options

Company News

GlobeNewswire
Mar 16th, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard...

Business Wire
Aug 20th, 2025
Altasciences Receives EcoVadis Gold Medal for Environmental, Social, and Governance (ESG) Efforts

EcoVadis, the world's most trusted provider of business sustainability ratings, has collaborated closely with Altasciences to enhance its environmental, social, and governance (ESG) initiatives, underscoring the company's commitment to a sustainable future and a reduced environmental footprint.

Yahoo Finance
Jul 31st, 2025
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment.

Postmedia Network
Mar 28th, 2025
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category

For 14 years, Outsourced Pharma's CDMO Leadership Awards have recognized the top-performing contract development and manufacturing organizations based on comprehensive industry research, and feedback from sponsors.

BioSpace
May 29th, 2024
Altasciences Receives 2024 CRO Leadership Award for Capabilities

Altasciences receives 2024 CRO Leadership Award for Capabilities.

INACTIVE